Small Molecule Inhibitors for MALT1 Protease and Scaffolding Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MALT1 inhibitors primarily target the protease activity of MALT1, leading to severe autoinflammation due to residual immune activation and impaired regulatory T cell function, limiting their therapeutic efficacy in treating neoplastic and inflammatory diseases.
Innovation Solution
Development of small molecule compounds that inhibit the interaction between BCL10 and MALT1, effectively blocking both protease and scaffolding activities of MALT1, thereby modulating T and B cell immune responses and downstream signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MALT1 protease inhibitors are used to block protease activity, then T cell activation is reduced, but severe autoinflammation occurs due to preserved scaffolding function and impaired Treg function
Solution Approach 1:
The invention segments the inhibition strategy by using two separate compounds: one that blocks MALT1 protease activity and another that blocks MALT1 scaffolding function. This allows independent control of the two functions, enabling complete inhibition of MALT1 signaling without the harmful effects of partial inhibition. The segmented approach resolves the contradiction by ensuring both protease and scaffolding activities are blocked simultaneously, preventing autoinflammation while maintaining immune activation control.
Solution Approach 2:
The invention employs a composite therapeutic strategy combining two distinct small molecule compounds with different mechanisms of action. The first compound (protease inhibitor) and second compound (scaffolding inhibitor) work synergistically to achieve complete MALT1 inhibition. This composite approach allows the therapeutic regimen to address both aspects of MALT1 function, resolving the technical contradiction between controlling immune activation and preventing autoinflammation.
2Productivity
If only protease activity is inhibited, then some immune activation is blocked, but regulatory T cell function is impaired leading to autoimmune pathology
Solution Approach 1:
The invention segments the inhibition approach into two distinct molecular targets: protease activity and scaffolding function. By using separate compounds for each target, the treatment can fully block MALT1-mediated Treg dysfunction without leaving residual scaffolding activity that would impair peripheral tolerance. This segmented strategy resolves the contradiction by ensuring comprehensive inhibition of all MALT1 functions that contribute to both immune activation and tolerance maintenance.
Solution Approach 2:
The invention changes the inhibition parameters from partial (protease only) to complete (protease plus scaffolding). By introducing a second compound that targets scaffolding function, the treatment regime transitions from incomplete inhibition to complete blockade of MALT1 activity. This parameter change resolves the contradiction by eliminating the residual scaffolding function that causes Treg impairment while maintaining the beneficial immune response modulation.
3Stability of the object's composition
If MALT1 scaffolding function is preserved, then some NF-κB signaling remains active, but this leads to severe autoinflammation in mice
Solution Approach 1:
The invention extracts and separately targets the scaffolding function of MALT1 using a dedicated small molecule compound. By removing the scaffolding activity through specific inhibition (while preserving protease activity in the absence of the second compound), the treatment eliminates the harmful autoimmune-like pathology caused by residual scaffolding function. This extraction approach resolves the contradiction by isolating and blocking the specific scaffolding-mediated harmful effects.
Solution Approach 2:
The invention changes the scaffolding function parameter from active to inhibited state through administration of the second compound. This parameter change completely blocks CBM complex assembly and NF-κB signaling activation that would otherwise lead to autoinflammation. By transitioning the scaffolding parameter from preserved to blocked, the invention resolves the contradiction between maintaining complex stability and preventing autoimmune pathology.
Data Source
AI summary
Small molecule inhibitors that block the interaction between B-cell lymphoma 10 protein (BCL10) and mucosa- associated lymphoid tissue lymphoma translocation protein 1 (MALT1), thereby inhibiting both the protease and scaffolding activities of MALT1, and MALT1- dependent downstream signaling, including IL-6 and IL-10 secretion by B-cell lymphoma cells and IL-2 transcription and secretion by Jurkat T cells.